StemCell Therapy

Trusted Business Insights answers what are the scenarios for growth and recovery and whether there will be any lasting structural impact from the unfolding crisis for the Hunter Syndrome Treatment market.

Trusted Business Insights presents an updated and Latest Study on Hunter Syndrome Treatment Market 2019-2026. The report contains market predictions related to market size, revenue, production, CAGR, Consumption, gross margin, price, and other substantial factors. While emphasizing the key driving and restraining forces for this market, the report also offers a complete study of the future trends and developments of the market.The report further elaborates on the micro and macroeconomic aspects including the socio-political landscape that is anticipated to shape the demand of the Hunter Syndrome Treatment market during the forecast period (2019-2029).It also examines the role of the leading market players involved in the industry including their corporate overview, financial summary, and SWOT analysis.

Get Sample Copy of this Report @ Hunter Syndrome Treatment Market Size, Share, Market Research and Industry Forecast Report, 2026 (Includes Business Impact of COVID-19)

Industry Insights, Market Size, CAGR, High-Level Analysis: Hunter Syndrome Treatment Market

The global Hunter syndrome treatment market size was valued at USD 864.9 million in 2018 and is expected to witness attractive growth over the forecast period. Introduction of novel therapies, robust product pipeline, rising government initiatives, and increasing awareness regarding Hunter syndrome and its available therapeutic options are expected to significantly fuel the market growth over the forecast period.Hunter syndrome, also known as mucopolysaccharidosis type II (MPS II), is a rare genetic disorder caused by an iduronate-2-sulfatase enzyme deficiency. Presently, there is no permanent cure for Hunter syndrome. Existing treatment including enzyme replacement therapy (ERT) and hematopoietic stem cell transplantation (HSCT) focuses on providing symptomatic relief and management of complications associated with the disease progression.

According to the data published by the National Institute of Health (NIH) in 2018, Hunter syndrome affects around 1 in 160,000 males globally. The risk of developing this disease is far less among women because they inherit two X chromosomes and one of them can provide a functioning gene if the other X chromosome is defective. However, in men, there is no other X chromosome to compensate for the defective one.Expected approval of novel therapies in late-phase clinical trials and increasing R&D activities by key players for the development of such novel therapies are anticipated to be two major factors driving the market growth in the near future. For instance, in June 2019, Denali Therapeutics Inc. received FDAs Orphan Drug Designation (ODD) and Rare Pediatric Disease Designation for its pipeline drug candidate DNL310, which is being evaluated for the treatment of the disease.Initiatives undertaken by various organizations for creating awareness regarding the disease diagnosis and its treatment is expected to support market growth over the forecast timeframe. For instance, in May 2018, Shire Plc. in collaboration with the National MPS Society and International MPS Network launched its third #FlyforMPS digital campaign aimed to increase awareness about .Treatment InsightsBased on treatment type, the market is categorized into enzyme replacement therapy (ERT), hematopoietic stem cell transplant (HSCT), and others. In 2018, the ERT segment accounted for the largest market share and is anticipated to hold onto its dominance over the forecast period. This is attributed to improved sales of Shire Plcs ELAPRASE and a potential for worldwide approval of GC Pharmas product called Hunterase.

Shire Plcs Elaprase (idursulfase) is the single major drug used for the treatment of Hunter syndrome, with GC Pharmas Hunterase (idursulfase beta) being approved only in South Korea as of now. These drugs have addressed a significant unmet need. However, the high cost of these drugs is expected to be a major factor hindering their market growth. For instance, Idursulfase (Elaprase) drug costs around USD 3,100 per 6mg/3ml vial.

Regional Insights of Hunter Syndrome Treatment Market

In 2018, North America dominated the market owing to favorable regulations for orphan drug development, rising awareness among people concerning rare diseases, increased funding for research activities, and improved healthcare facilities. Furthermore, the favorable reimbursement policies for expensive drugs such as ELAPRASE in the U.S. have supported its adoption and fueled the regional growth.Asia Pacific region is projected to exhibit a lucrative growth rate over the forecast period. Japan, China, and India are expected to emerge as potential countries for growth, owing to their high unmet needs in the market. Major players are focused on gaining approval for their novel therapies and are penetrating these markets to attain a major share. For instance, in July 2019, CANBridge Pharmaceuticals Inc. filed a New Drug Application (NDA) with the National Medical Products Administration (NMPA) for its novel treatment drug called Hunterase in China. Hunterase (idursulfase beta) is a patented therapy of GC Pharma indicated for the treatment of Hunter syndrome.

Market Share Insights of Hunter Syndrome Treatment Market

Some of the key players in the market comprise Shire Plc. (Takeda Pharmaceutical Company); GC Pharma; JCR Pharmaceuticals Co Ltd.; RegenxBio Inc.; Sangamo Therapeutics, Inc.; ArmaGen Inc; Inventiva S.A.; Denali Therapeutics Inc.; Bioasis Technologies Inc.; and Esteve.Currently, Shire Plc. (acquired by Takeda Pharmaceutical Company Limited in April 2019) is a prominent market player, with strong sales of its drug ELAPRASE, indicated for the treatment of Hunter syndrome. However, Shire plc is expected to face stiff competition from Green Cross (GC) Pharma over the forecast period. GC Pharma is emerging as a global player in the Hunter syndrome treatment market with its orphan drug, Hunterase.GC Pharma is undertaking inorganic growth strategies such as partnerships and collaborations for the commercialization and geographical expansion of Hunterase. For instance, in April 2019, Clinigen Group plc and GC Pharma entered into an exclusive licensing agreement under which Clinigen gained the rights to commercialize Hunterase in Japan.

Segmentations, Sub Segmentations, CAGR, & High-Level Analysis overview of Hunter Syndrome Treatment Market Research ReportThis report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest trends and opportunities in each of the sub-segments from 2015 to 2026. For the purpose of this study, this market research report has segmented the global Hunter syndrome treatment market report on the basis of treatment and region:

Treatment Outlook (Revenue, USD Million, 2019 2030)

Enzyme Replacement Therapy (ERT)

Hematopoietic Stem Cell Transplant (HSCT)

Others

Quick Read Table of Contents of this Report @ Hunter Syndrome Treatment Market Size, Share, Market Research and Industry Forecast Report, 2026 (Includes Business Impact of COVID-19)

Trusted Business InsightsShelly ArnoldMedia & Marketing ExecutiveEmail Me For Any ClarificationsConnect on LinkedInClick to follow Trusted Business Insights LinkedIn for Market Data and Updates.US: +1 646 568 9797UK: +44 330 808 0580

Read more:
Hunter Syndrome Treatment Market Analysis Of Global Trends, Demand And Competition 2020-2028 - 3rd Watch News

More than two million people in England still won't be able to see friends and family when lockdown rules are eased this weekend.

Rules are changing across the UK - with different numbers of people now allowed to meet up England, Wales, Scotland and Northern Ireland.

But for the 2.16million people told to 'shield' because they are clinically vulnerable, the rules won't change for some time.

George Eustice has warned that those shielding from coronavirus may have to continue to do so for several more months.

Asked about ways to make life easier for those who are shielding, the Environment Secretary told LBC: Well it is something that we are looking at because we completely recognise that those who are shielded and clinically vulnerable who have been told to isolate and not to see friends and family at all, that is going to start taking its toll on them and we want to be able to find ways to be able to do that.

But it is very, very difficult because they are clinically vulnerable and nobody obviously wants to visit family in that group and find that theyve given them the virus.

So we dont have answers yet, thats why they have to remain shielded for the time being, possibly for several more months.

He added that it is a difficult situation with that shielded cohort.

According to the NHS, if you have been identified as needing shielding - if you are at high risk of developing complications - you will have received a letter from your GP, hospital or (if identified nationally) from the national helpline.

Where the NHS holds a mobile number it will have also sent you a series of SMS text messages. These will come from either 07307 810357 or UK_Gov. If you are unclear why you have received a letter, contact your GP or hospital consultant.

You should register yourself on the gov.uk website if you need extra help and support. If you do not register on the website, then you will be contacted by the shielding helpline to confirm that you do not need support.

The call will be made from 0333 3050466. It is not a live telephone line, but if you call it you will get the recorded message: You were called today by the Shielding Helpline, sorry that we missed you, there is no need to call us back as we will try again soon. Thank you, goodbye.

Patients are at moderate risk of developing complications from coronavirus (COVID-19) where:

This includes the following patient groups:

Here is the original post:
Millions of people won't be able to see family for months says minister - MyLondon

My wife and I can both roll our tongues but our son can't. I'm worried about his paternity (Photo: Shutterstock)

I am a 36-year-old woman and have no children, but I am planning on having some in a few years. Is it true that with advancing age I increase my chances of getting a child with Downs syndrome or cerebral palsy?

ALSO READ: Ask the doctor: Covid-19 in children: What do we know?

Yes, these conditions have been associated with problematic pregnancies and abnormal foetal development. After age 35, older eggs tend to have abnormal cell division where the chromosomes may fail to separate in the correct way, leading to an excess number of expected chromosomes.

For example, in Downs syndrome, the foetus has an extra chromosome resulting in what is referred to as trisomy. Cerebral palsy is associated with complications of advanced parental age, especially the mothers. These may include miscarriages, multiple births, high blood pressure, gestational diabetes, and genetic mutations that impact brain development. Studies have also suggested that an older couple is more likely to use infertility procedures that can increase the risk of multiples and other risk factors.

I discovered that my fiances sister has albinism. How likely is it that any of our future children develops the condition?

There is a 50 percent chance your fiance is a carrier for the albinism gene. If this holds true, then there is a 25 percent chance that your future children may develop this condition.

My wife can roll her tongue (the rolling tongue gene). So can I. But our son, now 4, cant. I am worried about my childs paternity but dont want to stir the marriage yet. Do you think I should be worried or is there a genetic explanation?

There should be no cause to worry. More recent studies disputed the misleading assumption that leads to the conclusion that is worrying you. There was a study on identical twins who differed in their tongue-rolling trait, suggesting that the trait was not entirely under genomic influence as identical twins have the same genetic makeup.

I hope to get a child through a sperm bank. Do you think my request for physical characteristics of the sperm donor will help towards getting desirable traits in my future child?

ALSO READ: Ask the doctor: Is penile enlargement surgery considered plastic surgery? Does it work?

Yes, most physical characteristics are easily inherited from parents to their offspring. However, this could be a mixture of traits from both the donor and the recipient.

How far is the world from genetically engineering desirable traits into people and consequently having designer babies?

It is already happening on a smaller scale for certain traits, for example women or men going to sperm banks look for super straights in their donors for IVF procedures.

The world is also moving towards precision medicine, or what is commonly known as personalised medicine where everyone has their medicine tailor-made to suit their genes and condition based on their genetic fingerprint.

With technologies such as CRISPR/Cas9 gene editing, the future of designer babies is possible although ethical considerations in human cloning restrict such practices and may fail to promote advancements in these technologies.

Can I influence my childrens personalities or are they predetermined before birth?

To some extent yes, but personality is influenced by various factors. One component may come from the genes and the other from environmental interactions. For example, exposure to different life circumstances greatly influences ones personality.

ALSO READ: Why its better to have children before your 40s

My four-year-old twins are very different. My son has a real mean streak. Hes always been like that. His sister is kind. I have been responsible for their upbringing so far. Are character traits in the genes?

The difference could be in their genetic makeup. As we know, we inherit half of our genes from each parent and different personality traits could arise from this. In addition, the contrast in their personality could emanate from their daily interactions with the external world, such as from observations.

For More of This Stories Subscribe to the Standard Epaper to get a copy of Eve Woman in the Standard

You also have not told us if you treat the children differently whereby in most cases girls are treated kindly with lots of pampering, which is thus reflected in their behaviour. Boys who are often groomed to harden up to face the real world like men and turn out as brave warriors.

As a geneticist, do you think psychopaths are born or made?

I think it is a mixed bag of fortunes here. Psychopaths could result from nature and nurture. Several studies have pointed to the existence of genetic abnormalities in psychopaths, whereas other cases have risen purely from their upbringing. For example, we have had cases of sociopathic behaviour arising after traumatic experiences and drug addiction.Couples can undergo genetic testing to determine if they have any conditions their children can inherit (Photo: Shutterstock)

I have read a bit about genetic testing for couples, and I am considering it before we start a family. My question is, if they find something worrying (my sister died of sickle cell anaemia) can it be prevented because we know beforehand?

It may not be prevented in its entirety, but may help in early management of the outcome. It may also help in decision making whether to proceed and have children in the full knowledge that they may develop an inherited condition from parents. For your case, you could be a carrier for sickle cell disease and this prepares you to seek genetic therapy such as stem cell transplants to correct the abnormal red (sickle) cells.

I did the BRCA gene test and I have the mutated gene. What are the chances I could get ovarian or breast cancer?

A mutated BRCA gene is only an indicator of higher risk of developing either ovarian or breast cancer. It does not mean that you already have the cancer. It helps you prepare to seek and make a plan for testing and monitoring of signs of the development of these cancers so that preventative or management measures can be instituted. This may help in following a lifestyle that can reduce the chances of accelerating the development of the disease.

Is there a genetic explanation as to why children, especially firstborns, look like their fathers?

Well, it is not always the case. Physical characteristics of the offspring sometimes might be a mixture of both the mothers and fathers characteristics. There are, however, extremes where a child may look like a copy of either parent. A child is a result of the union of genes of a mother and father, and the strength of expression of these genes may differ.

There is conflicting information out there about genetically modified foods. What are the facts and fiction on this?

Genetically modified foods refer to food items whose source material production, be it plant or animal, involves intentional mixing (manipulation) of genetic material not naturally found in the pure/natural breed.

The fuss brought about by anti-GMO campaigners has been related, in my opinion, to a lack of information. The genes being included have their function known from a science point of view. However, genes may interact and the results may not be known fully. How a gene will behave in the new organism is assumed to be what is known, but it does not rule out undesired effects. However, before a gene is used in GMO, experimental tests are usually performed to understand different scenarios under which it may elicit undesired effects.

Dr Fredrick Nindo, a geneticist, is a visiting post-doctoral research fellow at the Mediterranean Infection Institute for Research in Cancer and Ageing, France.

Do not miss out on the latest news. Join the Eve Digital Telegram channel HERE.

Excerpt from:
Ask the doctor: Is there a chance I am not my sons father? - The Standard

A research report on Autologous Stem Cell and Non Stem Based therapies Market features a succinct analysis on the latest market trends. The report also includes detailed abstracts about statistics, revenue forecasts and market valuation, which additionally highlights its status in the competitive landscape and growth trends accepted by major industry players.

Autologous Stem Cell and Non Stem Based therapies Market: Global Size, Trends, Competitive, Historical & Forecast Analysis, 2019-2025. Rise in the prevalence of Cancer and Diabetes in all age groups population. Furthermore, the growing geriatric population is another key factor which drives the Autologous Stem Cell and Non Stem Based therapies Market.

Request for Methodology Report @https://brandessenceresearch.com/requestMethodology/PostId/61

Key Players

Autologous Stem Cell and Non Stem Based therapies Marketreports cover prominent players likeBioheart, Antrie Inc., Virxsys, Brainstorm Cell Therapeutics, TiGenix, Cytori Therapeutics Inc.,Tengion Inc.,Dendreon Corporation, Regeneus, Fibrocell, Genesis Biopharma, Orgenesis, Opexa Therapeutics,Neostem, U.S. Stem Cell Inc.,Vericel Corporation, Sanofi, IovanceBiotherapeutics Inc., Mesoblast Ltd., pluristem, Med Cell Europe AG, Anova IRM Stem Cell Center, Stemedica Cell Technologies Inc.,General Electric Company, BioRestorative Therapies,StemGenexamong,Aastrom Biosciences,NeoStem, Inc.,Virxsys, Genzyme Corporation and Georgia Health Science University.

Scope Of Market Reports

Autologous Stem Cell transplantation is a process in which cells from which all blood cells develop are removed, preserved and later given to the same person after severe treatment. In autologous stem cell transplantation, the patient itself acts as stem cell donor. These cells are collected in advance while they are in remission and returned to the patient at a later stage i.e., after two months. They are used to replace stem cells which have been impaired by high doses of chemotherapy.It is important to realize that the processes required in a stem cell transplant are lengthy and complicated. A transplant involves a lot of preparation and a lot of care after procedure. Many people have a single autologous stem cell transplant while others mainly having myeloma or tumors; have two or more continuous transplants.

The initial step in an autologous stem cell transplant is gathering the stem cells. Physicians usually collect stem cells from the bloodstream (peripheral blood stem cells) in advance. A mobilization treatment is used. When the stem cells are in the bloodstream, then collection process starts.The blood is separated using an Apheresis machine. This procedure requires a few hours, and is repeated until the appropriate amount of stem cells is collected. Once the stem cells are harvested, they are frozen in our Stem Cell Processing and Cryopreservation Laboratory until its time to transplant.

Autologous Stem Cell and Non Stem Based therapies Market is segmented on the basis of Application, product, End user and Geography. Based upon ApplicationAutologous Stem Cell and Non Stem Based therapies Market is classified as Neurodegenerative Disorders,Autoimmune Diseases, cancer &Tumors, Cardiovascular Diseases and Others. Based on the ProductAutologous Stem Cell and Non Stem Based therapies Market is classified into Blood Pressure Monitoring Devices, Pulmonary Pressure Monitoring Devices and Intracranial Pressure Monitoring Devices. On the basis of End users Autologous Stem Cell and Non Stem Based therapies Market is classified into Hospitals, Ambulatory Surgical Centers and Others.

Market Segmentation

By Application Analysis

By Product Analysis

By End User Analysis

The regions covered in Autologous Stem Cell and Non Stem Based therapies Market report are North America, Europe, Asia-Pacific and Rest of the World. On the basis of country level, Global Melanoma Drug Market sub divided in to U.S., Mexico, Canada, U.K., France, Germany, Italy, China, Japan, India, South East Asia, GCC, Africa, etc.

Market Dynamics

Rising prevalence of cancer and diabetes among people across all age groups, growing geriatric population, increasing demand for autologous stem cell and non-stem cell based therapies is another factor, which is likely to create a heightened demand. Moreover, Favorable reimbursement policies across several nations are also boosting market. Risks and complications associated with the Autologous Stem Cell and Non Stem Based therapy such as diarrhea, hair loss, nausea, severe infections, vomiting, heart complications, and infertility and thehigh cost of autologous cellular therapies ranging from $500,000 to $1,000,000 restraint the market. Innovation of some newtherapies with improved efficacy, fewer side effects are expected to offer good opportunity for growth of Autologous Stem Cell and Non Stem Based therapies Market in the future.

Regional Analysis

North America is probable to attain the largest share of the Autologous Stem Cell and Non Stem Based therapies Market in terms of revenue and expected to hold the position followed by Europe region. This is due to less risk related with the treatment. Also, the demand for these treatments is high due to their ability to cure a significant number of infectious diseases. Autologous stem cell and non-stem cell based therapies do not require an outside donor hence the treatment is less infectious and cheap. However, Asia Pacific is expected to show the high growth in the forecast period. The demand in this region will be led by countries such as China, India, Malaysia, and Vietnam. The demand is likely to grow as autologous stem cell and non-stem cell based therapies aid in the efficient management of cardiovascular diseases as well. Rising healthcare facilities as well as increasing tax and reimbursement procedures is also estimated to help in the growth of the autologous stem cell and non-stem cell based therapies market in the Asia Pacific.

Furthermore, increase in awareness of disease and government initiatives for improving health care facilities are expected to boost the regional market to a certain extent.

Market Reports

Get Full Report: https://brandessenceresearch.com/chemical-materials/autologous-stem-cell-therapies-market

About us: Brandessence Market Research and Consulting Pvt. ltd.

Brandessence market research publishes market research reports & business insights produced by highly qualified and experienced industry analysts. Our research reports are available in a wide range of industry verticals including aviation, food & beverage, healthcare, ICT, Construction, Chemicals and lot more. Brand Essence Market Research report will be best fit for senior executives, business development managers, marketing managers, consultants, CEOs, CIOs, COOs, and Directors, governments, agencies, organizations and Ph.D. Students. We have a delivery center in Pune, India and our sales office is in London.

Contact usat: +44-2038074155 ormail usat[emailprotected]

https://www.marketwatch.com/press-release/us-e-learning-market-2020-by-advanced-technologies-growth-opportunities-key-players-revenue-emerging-trends-and-business-strategy-till-2025-2020-05-25

https://www.marketwatch.com/press-release/europe-gan-semiconductor-devices-market-covid-19-pandemic-2020-industry-analysis-size-growth-share-trends-segmentation-and-forecast-to-2025-2020-05-25

See the original post:
Autologous Stem Cell and Non Stem Based therapies Market 2020 Global Industry Analysis, Trends, Growth Driver, Regional Study and Forecasts to 2025 -...

University Hospitals is participating in a study to determine if plasma donated from someone who's recovered from COVID-19 can improve the health of patients battling the virus.

Because patients who've recovered from COVID-19 have antibodies in their blood that could help fight the virus, it is thought that those suffering complications from COVID-19 might improve faster if they receive plasma from the people who've recovered, according to a news release.

Headed at the Christ Hospital in Cincinnati, the study currently has three participating sites in Ohio. Being a part of the study enhances UH's ability to quickly get plasma for patients who need it, according to the release.

"UH is at the forefront of experimental treatments including remdesivir, stem cell therapy and now convalescent plasma," cardiologist Dr. Steven Filby said in a prepared statement. "Patients suffering from extreme complications of COVID-19 have hope at UH thanks to these options."

Filby is a co-investigator for the study, along with Dr. Eiran Gorodeski, an internist and cardiologist at UH Cleveland Medical Center, and Dr. Katharine Downes, a pathologist.

Symptoms of COVID-19 include fever, fatigue, dry cough, headache and more. In addition to respiratory distress, COVID-19 can affect the cardiovascular system. No FDA-approved medicine currently exists to treat or prevent COVID-19, according to the release.

To receive plasmas as part of this study, patients must be hospitalized with COVID-19 and be experiencing "serious complications," including myocardial injury, according to the release.

Blood donations will be collected from patients who are determined recovered and cleared from COVID-19 and who are found to have developed antibodies in their plasma. UH is partnering with Hoxworth Blood Center and Vitalant to provide donations for the study.

"Offering experimental COVID-19 convalescent plasma transfusion to our patients gives us another option to fight COVID-19," Downes said in a prepared statement. "UH appreciates our partnership with the blood suppliers that are crucial to making this happen."

See the article here:
UH studying use of convalescent plasma to improve health of COVID-19 patients - Crain's Cleveland Business

SAN DIEGO, May 26, 2020 /PRNewswire/ --ViaCyte, Inc., a privately held regenerative medicine company, today announced the close of an approximately $27 million private financing, part of the Series D preferred stock financing entered into in late 2018. Investors included, Bain Capital Life Sciences, TPG Capital, RA Capital Management, Sanderling Ventures, and several individual supporters of the Company. Proceeds from the financing will be used to further advance the Company's multi-product candidate approach to develop medicines that have the potential to transform the way insulin-requiring diabetes is managed, potentially providing a functional cure for patients with type 1 diabetes.

Coinciding with the financing, the Company also appointed Ian F. Smithas Executive Chairperson. Mr. Smith was appointed to the Company's Board of Directors in July 2019 and succeeds Fred Middleton, who remains on the board.

Commenting on the financing, Paul Laikind, Ph.D., Chief Executive Officer and President of ViaCyte, said, "During these difficult times we are grateful for the continued support of our investors as well as our clinical trial participants, whose safety and health remains our focus and commitment. We are steadfast in our mission to deliver potentially life sustaining therapies for patients with insulin-requiring diabetes and to continue the significant progress we have made in the past year. ViaCyte is the first company to demonstrate production of C-peptide, a biomarker for insulin, in patients with type 1 diabetes receiving a stem cell-derived islet replacement. Moving forward, we are optimizing the effectiveness of both PEC-Direct and PEC-Encap, the latter of which incorporates novel device material technology created in collaboration with W.L. Gore & Associates. We are also making important progress on our PEC-QT program with our partner, CRISPR Therapeutics, and are now moving into pre-IND activities. This program is designed to eliminate the need for immuno-suppression and could have a transformative impact on a broader population of insulin-dependent patients."

Dr. Laikind continued, "In conjunction with the closure of the financing, we are also pleased to announce the appointment of Ian F. Smith as our Executive Chairperson, succeeding Fred Middleton. Since joining the board last July, Ian and I have worked closely to accelerate ViaCyte's growth and prepare for the future. We are extremely grateful to Fred for his many years of service as Chairperson of ViaCyte's Board of Directors. Throughout his time leading the Board, Fred provided expert guidance as ViaCyte has consistently broken new ground in the field of regenerative medicine and cell replacement therapies."

Mr. Middleton said, "I am proud to have chaired the Board as ViaCyte developed into a leading company in the regenerative medicine field.I am confident that Ian's unique expertise and executive leadership, specifically with innovative growth-oriented companies, and specifically in corporate strategy and operations, as well as capital markets will help ViaCyte progress its important work and firmly establish itself as a leader in the cell therapy sector."

About ViaCyte's Pipeline

The PEC-Direct product candidate, currently being evaluated in the clinic, delivers ViaCyte's PEC-01 cells (pancreatic islet progenitor cells) in a non-immunoprotective device and is being developed for type 1 diabetes patients who have hypoglycemia unawareness, extreme glycemic lability, and/or recurrent severe hypoglycemic episodes. The PEC-Encap (also known as VC-01) product candidate, also undergoing clinical evaluation, delivers the same pancreatic islet progenitor cells but in an immunoprotective device. PEC-Encap is being developed for all patients with type 1 diabetes. In collaboration with CRISPR Therapeutics, ViaCyte is developing immune-evasive stem cell lines from its proprietary CyT49 cell line. These immune-evasive stem cell lines, which are being used in the PEC-QT program, have the potential to further broaden the availability of cell therapy for all patients with insulin-requiring diabetes, type 1 and type 2. In addition, a pluripotent, immune evasive cell line has the potential to be used to produce any cell in the body, thus enabling many other potential indications.

About ViaCyte

ViaCyte is a privately held regenerative medicine company developing novel cell replacement therapies as potential long-term diabetes treatments to achieve glucose control targets and reduce the risk of hypoglycemia and diabetes-related complications. ViaCyte's product candidates are based on directed differentiation of pluripotent stem cells into PEC-01 pancreatic islet progenitor cells, which are then implanted in durable and retrievable cell delivery devices. Over a decade ago, ViaCyte scientists were the first to report on the production of pancreatic cells from a stem cell starting point and the first to demonstrate in an animal model of diabetes that, once implanted and matured, these cells secrete insulin and other pancreatic hormones in response to blood glucose levels and can be curative. More recently, ViaCyte demonstrated that when effectively engrafted, PEC-01 cells can mature into glucose-responsive insulin producing cells in patients with type 1 diabetes. To accelerate and expand its efforts, ViaCyte has established collaborative partnerships with leading companies including CRISPR Therapeutics and W.L. Gore & Associates. ViaCyte is headquartered in San Diego, California. The Company also has a robust intellectual property portfolio, which includes hundreds of issued patents and pending applications worldwide. ViaCyte is funded in part by the California Institute for Regenerative Medicine (CIRM) and JDRF. For more information on ViaCyte, please visit http://www.viacyte.comand connect with ViaCyte on Twitter, Facebook, and LinkedIn.

SOURCE ViaCyte, Inc.

Home

Read more from the original source:
ViaCyte Announces $27 Million Financing to Advance Next Generation Cell Therapies for Diabetes - PRNewswire

In the current situation of restricted movement and reduced workforce, (due to COVID-19 Pandemic) new technologies have been developed to provide end-to-end automation in different sectors such as food processing. Automated systems are hired by the companies to ensure continued supply and manufacturing of products with the least manual interference

The advent of Health Information Technology (HIT) components such as electronic health records (EHR), hospital information systems (HIS), picture archiving and communication systems (PACS), and vendor neutral archives (VNA) has had just as transformational an impact on the overall healthcare sector as the concerns regarding security and privacy. Data theft, undue access to personal health records, and cyber-attacks are very real threats that the healthcare sector faces today.

Myelofibrosis or osteomyelofibrosis is a myeloproliferative disorder which is characterized by proliferation of abnormal clone of hematopoietic stem cells. Myelofibrosis is a rare type of chronic leukemia which affects the blood forming function of the bone marrow tissue. National Institute of Health (NIH) has listed it as a rare disease as the prevalence of myelofibrosis in UK is as low as 0.5 cases per 100,000 population. The cause of myelofibrosis is the genetic mutation in bone marrow stem cells. The disorder is found to occur mainly in the people of age 50 or more and shows no symptoms at an early stage. The common symptoms associated with myelofibrosis include weakness, fatigue, anemia, splenomegaly (spleen enlargement) and gout. However, the disease progresses very slowly and 10% of the patients eventually develop acute myeloid leukemia. Treatment options for myelofibrosis are mainly to prevent the complications associated with low blood count and splenomegaly.

To Understand How Our Report Information Can Bring Difference, Ask for a brochure @https://www.persistencemarketresearch.com/samples/11341

The global market for myelofibrosis treatment is expected to grow moderately due to low incidence of a disease. However, increasing incidence of genetic disorders, lifestyle up-gradation and rise in smoking population are the factors which can boost the growth of global myelofibrosis treatment market. The high cost of therapy will the growth of global myelofibrosis treatment market.

The global market for myelofibrosis treatment is segmented on basis of treatment type, end user and geography:

As myelofibrosis is considered as non-curable disease treatment options mainly depend on visible symptoms of a disease. Primary stages of the myelofibrosis are treated with supportive therapies such as chemotherapy and radiation therapy. However, there are serious unmet needs in myelofibrosis treatment market due to lack of disease modifying agents. Approval of JAK1/JAK2 inhibitor Ruxolitinib in 2011 is considered as a breakthrough in myelofibrosis treatment. Stem cell transplantation for the treatment of myelofibrosis also holds tremendous potential for market growth but high cost of therapy is foreseen to limits the growth of the segment.

Looking for Exclusive Market Insights from Business Experts? Request a Custom Report here @https://www.persistencemarketresearch.com/request-customization/11341

On the basis of treatment type, the global myelofibrosis treatment market has been segmented into blood transfusion, chemotherapy, androgen therapy and stem cell or bone marrow transplantation. Chemotherapy segment is expected to contribute major share due to easy availability of chemotherapeutic agents. Ruxolitinib is the only chemotherapeutic agent approved by the USFDA specifically for the treatment of myelofibrosis, which will drive the global myelofibrosis treatment market over the forecast period.

Geographically, global myelofibrosis treatment market is segmented into five regions viz. North America, Latin America, Europe, Asia Pacific and Middle East & Africa. Northe America is anticipated to lead the global myelofibrosis treatment market due to comparatively high prevalence of the disease in the region.

Some of the key market players in the global myelofibrosis treatment market are Incyte Corporation, Novartis AG, Celgene Corporation, Mylan Pharmaceuticals Ulc., Bristol-Myers Squibb Company, Eli Lilly and Company, Taro Pharmaceuticals Inc., AllCells LLC, Lonza Group Ltd., ATCC Inc. and others.

The report covers exhaustive analysis on:

Regional analysis includes

Report Highlights:

Our unmatched research methodologies set us apart from our competitors. Heres why:PMRs set of research methodologies adhere to the latest industry standards and are based on sound surveys.We are committed to preserving the objectivity of our research.Our analysts customize the research methodology according to the market in question in order to take into account the unique dynamics that shape the industry.Our proprietary research methodologies are designed to accurately predict the trajectory of a particular market based on past and present data.PMRs typical operational model comprises elements such as distribution model, forecast of market trends, contracting and expanding technology applications, pricing and transaction model, market segmentation, and vendor business and revenue model.

See the article here:
Global Myelofibrosis Treatment Market to Register Growth in Incremental Opportunity During the Forecast Period 2016 2022 - Cole of Duty

Breast cancer remains a major global healthcare concern despite exceptional levels of public awareness about the disease. A lack of clear causative environmental factors and hereditary dispositioning have resulted in the incidence of breast cancer continuing to rise, a trend which is expected to continue into the immediate future.

In the UK, breast cancer is the leading type of cancer in women, with there being over 54,900 cases diagnosed each year. Although early-stage cancer is relatively treatable and has good 5- and 10-year disease-free survival rates, 10% of cancers are diagnosed late. Additionally, there are no treatments for metastatic breast cancer, which ultimately results in death.

Get Free Sample PDF (Including Full TOC, Tables And Figures) of Market @https://www.researchmoz.us/enquiry.php?type=S&repid=1877885

As a whole, this presents a huge unmet clinical need in the breast cancer treatment algorithm. The treatment algorithm for breast cancer focuses on two main themes: standard chemotherapy and drugs that target hormones, namely estrogen and progesterone. However, chemotherapy and hormone drugs only make up a small percentage of the drug pipeline and an even smaller percentage of first-in-class products.

New trends in oncology are present in the breast cancer pipeline, in particular the focus on extracellular matrix degradation and improving the immune response to tumors. This report focuses on the epidemiology, pathophysiology and existing treatment options for breast cancer before giving detailed insight into promising pipeline targets and deal activity in the breast cancer market.

Scope

Unmet need is extremely high in late-stage breast cancer. What are the most important etiological risk factors and pathophysiological processes implicated in breast cancer? What is the current treatment algorithm? How effective are current therapies for these indications, and how does this impact prognosis? The breast cancer pipeline is large and contains a very high proportion of first-in-class product innovation. Which molecule types and molecular targets are most prominent across the breast cancer pipeline? What are the relationships between established and up-coming molecular targets in breast cancer? Which first-in-class targets are most promising? How does first-in-class target diversity differ by stage of development and molecular target class? The deals landscape is active and dominated by very high and very low deal values. Which indications attract the highest deal values? How has deal activity fluctuated over the past decade? Which first-in-class pipeline products have no prior involvement in licensing or co-development deals?

Enquiry For Discount or to Get Customized Report @https://www.researchmoz.us/enquiry.php?type=D&repid=1877885

Reasons to buy

Appreciate the current clinical and commercial landscapes by considering disease symptoms, pathogenesis, etiology, co-morbidities and complications, epidemiology, diagnosis, prognosis and treatment options. Identify leading products and key unmet needs within the market. Recognize innovative pipeline trends by analyzing therapies by stage of development, molecule type and molecular target. Assess the therapeutic potential of first-in-class targets. Using proprietary matrix assessments, first-in-class targets in the pipeline have been assessed and ranked according to clinical potential. Consider first-in-class pipeline products with no prior involvement in licensing and co-development deals, which may represent potential investment opportunities.

1 Table of Contents1 Table of Contents 21.1 List of Tables 41.2 List of Figures 42 Executive Summary 62.1 Exceptionally Large and Innovative Pipeline 62.2 Alignment of First-in-Class Molecular Target with Disease Causation 62.3 Highly Active Deals Landscape with Numerous Investment Opportunities 63 The Case for Innovation 73.1 Growing Opportunities for Biologic Products 73.2 Diversification of Molecular Targets 83.3 Innovative First-in-Class Product Developments Remain Attractive 83.4 Regulatory and Reimbursement Policy Shifts Favor First-in-Class Innovation 93.5 Sustained Innovation in Breast Cancer 93.6 Report Guidance 94 Clinical and Commercial Landscape 114.1 Overview of Breast Cancer 114.2 Symptoms 114.3 Diagnosis 114.4 Etiology 124.4.1 Age and Gender 124.4.2 Genetics 124.4.3 Environmental 134.5 Pathophysiology 134.5.1 Tumor Initiation and Aberrant Cell Proliferation and Survival 134.5.2 Tumor Metabolic Shift 144.5.3 Tumor Progression, Micro-environment Alteration and Angiogenesis 154.5.4 Cancer Stem Cells 164.6 Epidemiology 164.7 Complications 174.8 Prognosis and Disease Staging 184.8.1 Classification 194.9 Introduction to Breast Cancer Treatments 204.9.1 Treatment Algorithm 204.9.2 Treatment Options for Breast Cancer 224.10 Overview of Marketed Products in Breast Cancer 264.11 Current Unmet Needs in the Breast Cancer Market 275 Assessment of Pipeline Product Innovation 295.1 Overview 295.2 Breast Cancer Pipeline by Phase of Development and Molecule Type 295.3 Pipeline by Molecular Target 305.4 Comparative Distribution of Programs between the Market and Pipeline by Molecular Target Class 325.5 Comparative Distribution of First-in-Class and Non-First-in-Class Pipeline Programs by Molecular Target Class 325.5.1 Percentage Distribution of First-in-Class and Non-First-in-Class Pipeline Programs 355.6 Ratio of First-In-Class Programs to First-in-Class Molecular Targets within the Pipeline 365.7 List of All First-in-Class Pipeline Programs 38

For More Information Kindly Contact:ResearchMozMr. Rohit Bhisey,Tel: +1-518-621-2074USA-Canada Toll Free: 866-997-4948Email:[emailprotected]Follow us on LinkedIn @http://bit.ly/1TBmnVGMedia Release:https://www.researchmoz.us/pressreleaseFollow me on :http://marketresearchlatestreports.blogspot.com/

See the rest here:
Most Definitive & Accurate Study on Frontier Pharma: Breast Cancer First-in-Class Innovation Underlies Immunotherapeutic Potential and Pipeline...

An assistant parish priest in the UAE has died after suffering from multiple complications arising from Covid-19.

Father Youssef Sami Youssef, 62, served the Arabic-speaking community at St Michaels Church Sharjah.

The outgoing and lively priest had been receiving treatment, including ventilation and stem-cell therapy, at Sheikh Khalifa Medical City, Ajman.

But his condition continued to deteriorate and he died on Sunday as a result of multiple organ failure.

Fr Youssef was under treatment for almost three weeks at the multi-speciality hospital and received expert care, ventilation and stem cell therapy, the Apostolic Vicariate of Southern Arabia said.

However since he already had some underlying medical conditions, he soon started to develop critical multiple organ failure.

The vicariate said his outgoing and lively personality would be sorely missed by all who knew him, especially the Arabic and French-speaking Catholics in the vicariate, where he served several churches throughout his career.

More than 700 parishioners paid tribute to Fr Youssef on the vicariates Facebook page, where his death was announced to his congregation.

May his soul rest in peace. I used to attend his Masses when he served in Abu Dhabi, wrote one.

Father Youssef was a humble man, I heard that he lived a difficult life, as he lost so many family members in the Lebanese war, yet he kept the faith.

He is without a doubt in the Lord's heavens. A good humble man he was, a faithful priest and a caring soul. May God have mercy on your soul Father. We will miss you.

Another wrote he would remember his smile.

Even though I never interacted with him so much ... but he was one person I came across with a smile when I used to see him before the Sunday 8pm Mass. Rest in peace, Father.

Born in Lebanon in 1957, Father Youssef joined the Order of Friars Minor Capuchin of the General Custody of the Near East in 1977, and was ordained to the priesthood 11 years later.

He had been a missionary in the Gulf region since 1993, and served several UAE communities, including St Marys Church in Dubai, St Josephs Cathedral Abu Dhabi and St Marys Church Al Ain.

He was also stationed in Doha and Manama for a time between 2004 and 2011. But since 2016, he served St Micheals Church Sharjah.

Details of his burial and memorial Mass have yet to be made public.

Updated: May 18, 2020 03:31 PM

Read more:
Coronavirus: assistant parish priest in Sharjah dies from complications of the disease - The National

BOSTON--(BUSINESS WIRE)--Gamida Cell Ltd. (Nasdaq: GMDA), an advanced cell therapy company committed to finding cures for blood cancers and serious blood diseases, today announced positive topline results from its Phase 3 clinical study evaluating the safety and efficacy of omidubicel, an investigational advanced cell therapy in development as a potential life-saving treatment option for patients in need of bone marrow transplant. The median time to neutrophil engraftment was 12 days for patients randomized to omidubicel compared to 22 days for the comparator group (p<0.001). Neutrophil engraftment is a measure of how quickly the stem cells a patient receives in a transplant are established and begin to make healthy new cells, and rapid neutrophil engraftment has been associated with fewer infections and shorter hospitalizations.1

Despite the curative potential of bone marrow transplant, it is estimated that more than 40 percent of eligible patients in the United States do not receive a transplant for various reasons, including the lack of a matched donor.2 Even for patients who do receive a transplant, treatment is not always effective and can lead to serious complications that can dramatically affect their quality of life.3 Omidubicel is intended to address the current limitations of bone marrow transplant by providing a therapeutic dose of stem cells while preserving the cells functional therapeutic characteristics.

Im very encouraged by the data from this rigorous, Phase 3 study that was conducted at more than 50 centers around the world, as there is a significant need for new bone marrow transplant graft modalities, said Mitchell Horwitz, M.D., principal investigator and professor of medicine at the Duke Cancer Institute. These results have the potential to substantially move the field forward and represent an important step toward making stem cell transplantation more accessible and more successful for patients with lethal blood cancers. Shortening the time to engraftment is clinically meaningful, as it can reduce a patients time in the hospital and decrease likelihood of infection.

Omidubicel is the first bone marrow transplant product to receive Breakthrough Therapy Designation from the U.S. Food and Drug Administration and has the potential to be the first FDA-approved bone marrow transplant graft. We are very pleased with the results of the Phase 3 data reported today, which move us one step closer toward bringing potentially curative therapies to patients. We expect to begin to submit our biologics license application for omidubicel to the FDA on a rolling basis in the fourth quarter of this year, stated Julian Adams, Ph.D., chief executive officer of Gamida Cell. We deeply appreciate the participation of patients in this trial and the support we have received from investigators and their teams.

Topline Phase 3 Data

The international, multi-center, randomized Phase 3 study (NCT02730299) was designed to evaluate the safety and efficacy of omidubicel in patients with high-risk hematologic malignancies undergoing a bone marrow transplant compared to a comparator group of patients who received a standard umbilical cord blood transplant. The primary endpoint was time to neutrophil engraftment. The intent-to-treat analysis included 125 patients aged 1265 years with acute lymphoblastic leukemia, acute myelogenous leukemia, chronic myelogenous leukemia, myelodysplastic syndrome or lymphoma and was conducted at more than 50 clinical centers in the United States, Latin America, Europe and Asia. The demographics and baseline characteristics were well-balanced across the two study groups.

The study achieved its primary endpoint (p<0.001). In the intent-to-treat analysis, the median time to neutrophil engraftment was significantly shorter for patients who received omidubicel (12 days; 95% CI: 10-15 days) compared to the comparator group (22 days; 95% CI: 19-25 days). Omidubicel was generally well tolerated. Among patients who were transplanted per protocol, 96 percent of patients who received omidubicel achieved successful neutrophil engraftment, compared to 88 percent of patients in the comparator group.

We are pleased with the outcome of this global, well-designed study in patients with life-threatening blood cancers who were in need of a bone marrow transplant and did not have an available matched donor, said Ronit Simantov, M.D., chief medical officer of Gamida Cell. Importantly, these data confirmed the results from our earlier Phase 1/2 clinical study and demonstrated that patients who received omidubicel had more rapid recovery of neutrophils, which are key infection-fighting white blood cells.

The data reported today are consistent with results from a multi-center, Phase 1/2 study in 36 patients with advanced hematologic malignancies, which showed that patients treated with omidubicel demonstrated more rapid neutrophil engraftment compared to a concurrent cohort of 146 patients treated with standard umbilical cord blood as reported by the Center for International Blood and Bone Marrow Transplant Research.4 In the Phase 1/2 study, the median time to engraftment was 11.5 days (95% CI: 9-14 days) for omidubicel recipients compared to 21 days (95% CI: 20-23 days) for the CIBMTR cohort (p<0.001).

Gamida Cell expects to report full efficacy and safety results at a medical conference later this year.

Conference Call Information

Gamida Cell will host a conference call today, May 12, 2020, at 8:30 a.m. ET to discuss the Phase 3 study results. A live webcast of the conference call can be accessed in the Investors section of Gamida Cells website at http://www.gamida-cell.com. To participate in the live call, please dial 1-866-930-5560 (domestic toll-free), 1-409-216-0605 (international) and refer to conference ID number 5454076. A recording of the webcast will be available approximately two hours after the event, for approximately 30 days.

About Omidubicel

Omidubicel, the companys lead clinical program, is an advanced cell therapy under development as a potential life-saving allogeneic hematopoietic stem cell (bone marrow) transplant solution for patients with hematologic malignancies (blood cancers). Omidubicel is the first bone marrow transplant product to receive Breakthrough Therapy Designation from the U.S. Food and Drug Administration and has also received Orphan Drug Designation in the U.S. and EU. In both Phase 1/2 and Phase 3 clinical studies, omidubicel demonstrated rapid and durable time to engraftment and was generally well tolerated. Omidubicel is also being evaluated in a Phase 1/2 clinical study in patients with severe aplastic anemia.5 The aplastic anemia investigational new drug application is currently filed with the FDA under the brand name CordIn, which is the same investigational development candidate as omidubicel. For more information on clinical trials of omidubicel, please visit http://www.clinicaltrials.gov.

Omidubicel is an investigational therapy, and its safety and efficacy have not been evaluated by the U.S. Food and Drug Administration or any other health authority.

About Gamida Cell

Gamida Cell is an advanced cell therapy company committed to finding cures for blood cancers and serious blood diseases. We harness our cell expansion platform to create therapies with the potential to redefine standards of care in areas of serious medical need. For additional information, please visit https://www.gamida-cell.com.

Cautionary Note Regarding Forward Looking Statements

This press release contains forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995, including with respect to the patient enrolment in and timing of initiation and progress of and data reported from the clinical trials of Gamida Cells product candidates, anticipated regulatory filings, and potential approval of product candidates by the U.S. Food and Drug Administration, which statements are subject to a number of risks, uncertainties and assumptions, including, but not limited to the ongoing global COVID-19 pandemic; the scope, progress and expansion of Gamida Cells clinical trials and variability, and ramifications for the cost thereof; and clinical, scientific, regulatory and technical developments. In light of these risks and uncertainties, and other risks and uncertainties that are described in the Risk Factors section and other sections of Gamida Cells Annual Report on Form 20-F, filed with the Securities and Exchange Commission (SEC) on February 26, 2020, and other filings that Gamida Cell makes with the SEC from time to time (which are available at http://www.sec.gov), the events and circumstances discussed in such forward-looking statements may not occur, and Gamida Cells actual results could differ materially and adversely from those anticipated or implied thereby. Any forward-looking statements speak only as of the date of this press release and are based on information available to Gamida Cell as of the date of this release.

1Anand S., Thomas S., Hyslop T., Adcock J. et al. 2017. Transplantation of Ex Vivo Expanded Umbilical Cord Blood (NiCord) Decreases Early Infection and Hospitalization. BBMT 2017; 23:1151-7.2U.S. Department of Health and Human Services: Health Resources and Services Administration. Bone Marrow and Cord Blood Donation and Transplantation.3Carreras et al. The EBMT Handbook. Springer 2019.4Horwitz M.E., Wease S., Blackwell B., Valcarcel D. et al. 2018. Phase I/II study of stem-cell transplantation using a single cord blood unit expanded ex vivo with nicotinamide. Journal of Clinical Oncology. DOI: 10.1200/JCO.18.000535www.clinicaltrials.gov, NCT03173937.

View original post here:
Gamida Cell Announces Positive Topline Data from Phase 3 Clinical Study of Omidubicel in Patients with High-Risk Hematologic Malignancies - Business...

Whether youre a big fan of the New York Times cooking section or just live for Twitter drama, .

odds are that youre familiar with

the Alison Roman and Chrissy Teigen fight that went down recently.

In summary: Alison Roman

called Chrissy Teigens

cooking empire a content farm, .

Chrissy tweeted that she was bummed out by the hateful words.

Alison publicly apologized,

and both Chrissy and her fans were (mostly) placated.

many Teigen fans were also

tweeting in support of

her brand Cravings, .

noting how much success

its had with both her cookbook and her products at Target.

Your nonstick frying pans are the best pans

Ive ever cooked with, one person said. I have 2,

and I treat them like theyre the last 2 on Earth.

reviewers love the two-pack aluminum frying pan set as

much as Twitter users do.

This set of pans is top quality! one reviewer raved.

You can tell just by the feel and look of them. I used on

my electric stove and they cooked nicely and evenly.

Read the original post:
The Alison Roman and Chrissy Teigen feud was the best thing that ever happened to my cooki - Yahoo Lifestyle

A Tik Tok user is drawing praise online after sharing her hack for cleaning fruit

and the gross reason its necessary.

The video, posted by Seleste Radcliffe,

shows what can happen when

someone uses saltwater...

to clean a store-bought

package of strawberries.

Radcliffe, who demonstrates

the rinsing method in her clip.

quickly explains its importance: Salt,

as it turns out, helps draw out the bugs.

The realization that there are often

tiny bugs living inside strawberries...

came as an unfortunate surprise to both Radcliffe and many of her followers.

During growing, harvesting and packaging, bugs find their way into all kinds of food according to the Scientific American.

The tiny creatures are actually relatively common in many items:.

For example, canned juices can possibly contain one maggot for every 250 milliliters.

Those facts didnt stop TikTok users

from sharing their disgust though.

Never eating strawberries

again, one user wrote

Excerpt from:
Thanks to TikTok, now we know there are bugs in our strawberries - Yahoo Lifestyle

Matt Thompson ofThompson Wood Artuses his woodworking skills to create ridiculous and unnecessary things. Some of these products include a chair thatpats you on the backand anautomatic dog petter.But its really his Ultimate Picnic Table, that would be perfect for thewarm weather.

The massive contraption is an outdoor table that serves guests hot dogs and beer.Thompson used a pulley system to control some of the mechanisms like the beer dispenser. Guests just press down on the under-table pedal to release a can from the built-in wooden cooler. The picnic table also comes fitted with a hot dog grill.

It works just like a conveyor belt.When the hot dogs finish cooking, a robotic mechanism pushes them to the output pile. Then hungry guests can grab a dog and slather it in ketchup or mustard from the condiments dispenser. It very much is the ultimate grill for a lazy day.

Thompsons inventions arent usually for sale. But Facebook users were still pretty impressed by the picnic table even if they can never get their hands on one.

Are you kidding me??? How do you think of all these inventions? This table is awesome! OneFacebook user wrote.

This is epic! Awesome how the hot dogs are mustarded evenly,another said.

I wish I had your brain! Lol,one person said.

If you enjoyed this story, you might like to read abouthow you can upgrade your setup while working from home.

More from In The Know:

This 15-foot-tall exoskeleton was made for racing

A giant panda in China gave birth to twins and the video is unreal

Little boy thrilled to see grandparents through glass door

This queer-owned brand makes natural skincare and makeup accessible

The post This picnic table handles everything for you from hot dogs to beer appeared first on In The Know.

Read the original:
This picnic table handles everything for you. - Yahoo Lifestyle

Photo credit: Instagram

From Cosmopolitan

Kelley Flanagan posted a video of her dancing with Peter Weber on TikTok.

In response to the vid, a fan rudely told Kelley it was a waste watching Peters season of The Bachelor.

Everyone knows The Bachelor and The Bachelorette rarely wrap with perfect endings these days. Take Peter Webers season of The Bachelor, for example, which was a whole delightful mess. He proposed to Hannah Ann Sluss then dumped her for Madison Prewett, whom he dated for all of five minutes. But hey, at least he ended up with Kelley Flanagan! Despite *that* happy ending, some fans are still less than impressed that they invested two months into the show only for Kelley and Peter to end up together.

On TikTok, Kelley posted a super fun video of her dancing with Peter. You know, now that theyre finally done with keeping their very obvious relationship a secret.

Its truly a sight to behold:

A commenter on the video wasnt pleased with Kelley and Peters display of affection though. You mean to tell me I wasted every Monday instead of studying for this, the user wrote (rudely), to which Kelley responded, Lol you should have been studying! Which, fair!

Of course, this isnt the first time Peter and Kelley have uploaded lovey-dovey TikTok videos together. Remember that one time Kelley and Peter threw it alllll the way back and posted a video of them singing Akons Nobody Wanna See Us Together on TikTok? No? Welp, allow me to refresh your memory:

All this just goes to show that things between Kelley and Peter are moving along swimmingly, no matter what their haters (in and out of Bachelor Nation) have to say about their relationship. And thats that on that!

You Might Also Like

Go here to see the original:
Kelley Flanagan Responded to a TikTok User Who "Wasted Every Monday" Watching 'The Bachelor' - Yahoo Lifestyle

Little Lula learnt to stand at just eight weeks old. (SWNS)

A dad whose baby learned to stand at just eight weeks old has joked she may have been inspired by watching him view strongman clips on YouTube.

Tezra Finn-Johnston, 31, and girlfriend Emily Derrick, 23, from Kingswood, Bristol, first noticed their daughter Lulas strength when they left hospital after her birth.

Even at that early stage she was able to support her own head, they say.

Little Lula was born on 31 January weighing just 5lbs 9oz and was on the fifth percentile, which means she weighed less than 5% of other babies the same age.

Now 15 weeks old, the tot is able to stand unassisted, supporting her own weight.

Read more: Mum gives birth to IVF baby in bereavement suite while suffering from coronavirus

The new dad first spotted his daughters unusual leg strength when she was around a month old.

She was having a tantrum and I tried to sit her on my knee to calm her, Finn-Johnston says.

Instead of sitting down, she just stood on my knee and wouldnt bend her legs.

She did it a few more times later on in the weeks eventually I thought, well, if she can do it while shes annoyed, maybe she can do it when shes happy.

Finn-Johnston decided to test his theory and after he held and supported his daughter, she managed to take her own weight.

The couple dont know anyone else with a baby who was able to do any of those things so early.

Everyone seems to think that its unusual that she can hold herself up, even just sitting, let alone standing, he says.

From everything Im reading, it should be about nine months to a year that they should be able to support their own weight.

Read more: Teacher gives birth in supermarket car park after paramedic misses plea for help

The first-time parents originally noticed their daughter seemed unusually strong when they brought her home from the hospital, five days after she was born.

Pretty much from the day we left hospital she was able to support her head a little bit more than we thought she should be able to, Finn-Johnston says.

Story continues

She was holding it up for a few seconds and that shouldnt be for a few weeks, but pretty much straight away she was able to do that.

Then we watched the Babies documentary on Netflix and on there they said babies are inherently programmed to crawl from birth.

So I put her down on the mat and she was trying to crawl a bit.

Then I put my arm behind her and she was able to push herself up the mat propelling herself from my hand with her legs.

She can also do it lying on her front as well.

Read more: New dad who lost his right testicle to cancer celebrates the birth of baby

While Finn-Johnston doesnt recommend people try similar things with their own babies, he believes his daughter enjoys showing off her new skills.

Its like shes showing off she looks at you and smiles, its like shes trying to be a big girl!

The dad is a big fan of strongman competitions, regularly watching videos on Youtube.

He believes Lula looks engaged when they watch the videos together and jokes she might have been inspired by the clips.

She sits on my knee and we both watch that, so I like to think she is training herself, he jokes.

While Lula isnt able to walk just yet, her parents believe her first steps might be closer than they think.

She just seems a lot older than she actually is, her mum says.

Im just like, oh dont grow up yet!

According to Babycentre UK, babies have the reflexes needed to stand from birth, by bracing their legs against a surface they feel underfoot.

If you hold your newborn upright on your lap, supporting his head, you'll feel him trying to use his legs. He's not trying to walk, its just basic instincts kicking in, the site says.

It goes on to explain that babies legs arent nearly strong enough to stand at this age and that the reflex will disappear after a couple of months.

Read more: Parents spot baby's eye cancer in picture taken with a flash

Berkshire Healthcare NHS has produced an early-years toolkit that explains how parents can safely encourage their baby to stand.

Your child can be held supported in a standing position from an early age, the toolkit explains.

This allows the child to experience the feeling of their body weight through their feet.

The site says babies may bounce up and down, which they do to develop the strength in their leg muscles.

You can stand your child in many different ways, for example on your lap when you are sitting in a chair, in front of a coffee table or sofa or on the sofa cushion next to you with their back against the back cushions, the toolkit continues.

As they get stronger, they will need less support from you and they will use their hands on the furniture to support themselves more.

When they can stand briefly without holding on, they are ready to learn to step along the furniture or cruise.

Additional reporting SWNS.

See the rest here:
Parents amazed when baby learns to stand at just eight weeks old - Yahoo Lifestyle

Photo credit: Collegiate Images - Getty Images

From Cosmopolitan

The University of Kentucky fired its entire cheerleading coaching staff and its advisor after a three-month investigation.

The university claimed its staff "failed to provide reasonable oversight during off-campus events."

The university cited alleged incidents of alcohol use, hazing, and public nudity.

The University of Kentucky just released a bombshell statement following a three-month probe into the school's cheerleading team, which is most known for winning 24 national championships in the last 35 years. In an effort to "protect students and ensure the integrity of the nations premier collegiate cheerleading program," the university fired its entire coaching staff after administrative officials found incidents of alleged hazing, alcohol abuse, and public nudity.

Head Coach Jomo Thompson and Assistant Coaches Ben Head, Spencer Clan, and Kelsey LaCroix were all "dismissed" when the university determined they "failed to provide reasonable oversight during off-campus events." The team's adviser of four decades, T. Lynn Williamson, also demonstrated poor oversight and judgement in the eyes of the university. However, Williamson was not fired because he retired days after learning about the school's investigation and after "being directed to have no contact with the cheerleading squad."

According to the school, the investigation began when a family member reported a party-like atmosphere during a team retreat in February. More than 60 students, coaches, and administrators in the cheer program were interviewed over the course of three months, and several disturbing accusations were made.

At the Lake Cumberland retreat in February, some cheerleaders performed "basket tosses," and lobbed topless or bottomless teammates off a dock and into the water. The school went on to say that these stunts "were done at the direction of other members of the squad and within the view of at least some of the coaches."

Story continues

The University of Kentucky also claimed the coaches allowed alumni to bring boats and alcohol to Lake Cumberland and didn't stop any of the students from drinking, which lead to some needing medical attention.

And during a different retreat in Tennessee, some cheerleaders allegedly instructed their teammates to "perform lewd chants and wear outfits that did not include underwear."

On top of all of that, the University found conflicts of interest for two coaches who had their own gymnastics businesses and hired some of the squad members. There were also incidents of Williamson hiring the coaches and students "to perform work at his home."

In addition to beginning the search for new coaching staff, the University of Kentucky has banned the team's annual retreat and will increase supervision during off-campus trips. "Cheerleading squad members will be held to the same standards as all our student athletes," said the executive associate athletics director, Sandy Bell. "Its a new day for UK cheerleading."

You Might Also Like

More here:
The University of Kentucky Fired Its Entire Cheerleading Coaching Staff Amid Public Nudity and Hazing Allegations - Yahoo Lifestyle

Photo credit: Adam Gault - Getty Images

From Women's Health

In Dr. Pimple Popper's latest Instagram video, she tackles so many cysts all over her patient's bodies.

One of the cysts pops out and flies across the room.

Dr. Pimple Popper uses her fingers to squeeze them all out and help each patient find relief.

It's a bird. It's a plane. It's a... pimple! If you're around dermatologist Sandra Lee, MD, a.k.a. Dr. Pimple Popper's office that is likely what you'll see flying through the air.

In her latest Instagram videos, she tackles multiple cysts on multiple patients. The cysts are all different shapes and sizes. Some go quietly, but most pop out with a real bang.

Take this cyst lodged in her patient's scalp for example. Dr. Pimple Popper captions this video: "Pop on the loose! #drpimplepopper" You have to see this pop to believe it. Dr. Pimple Popper squeezes and presses super hard until the cyst finally squeaks out to the surface. (Truly, she tells her patient to push back against her.)

Once the cyst is out, it keeps going. It jumps right out of her patient's head and almost hits the floor. The catch is out of frame, but it's pretty safe to assume Dr. Pimple Popper or one of her talented assistants caught it in mid-air.

Her fans can hardly believe their eyes. One wrote: "That is the first time I have seen one jump out to begin its life on the outside! #drpimplepopper" Another fan added, "Like a ball of old gum "

Dr. Pimple Popper didn't stop there. She plopped the cyst on the table and sliced it right open. Ask the doc and you shall receive, folks!

Phew, that was a lot, but perhaps you'd prefer a messier cyst-uation. (I gotchu!) Dr. Pimple Popper's next patient had a large cyst ready to let loose. This cyst calls for the punch biopsy tool. As soon as the derm punches it, the white goo inside starts gurgling out.

Story continues

Dr. Pimple Popper has not one but two cysts in need of a punch. The next cyst is even bigger and messier. She grabs her punch biopsy tool and goes right to work. After the punch, comes the ooey gooey squeeze.

Her fans are mesmerized by this pop. One Popaholic wanted to know more ad asked, "Curious...why a punch on the face? Would have thought incision would have less of a scar"

Last but not least, Dr. Pimple Popper takes care of a "lima bean" cyst with a whacky new technique. She hooks a thread to the cyst and simultaneously pulls and squeezes until it emerges out of the skin. All that's left is a lima bean cyst dangling on the string.

Dr. Pimple Popper calls this one a "flying pop." The cyst does dangle in mid-air like it's flying. Whether it was punching, jumping, or flying, there was a cyst pop for everyone this weekend.

You Might Also Like

Originally posted here:
Dr. Pimple Popper Just Squeezed A Cyst That Jumped Right Out Of Her Patient's Head - Yahoo Lifestyle

The football world was left aghast when news dropped of Todd Gurley having an arthritic knee. From that point, its been a waiting game for the worst.

Would Gurley still be a viable starting runner? Would his career have to be cut short?

2019 provided a bit of an answer. Gurley finished as the RB14 in half-point-PPR Yahoo fantasy formats. He wasnt as efficient as previous years, but he still managed to score 14 total touchdowns thats great for a fantasy bottom-line. And maybe that 2019 production gave the Atlanta Falcons a feeling of reassurance, who signed the running back to a one-year deal after the Rams released him.

[Create or join a 2020 Yahoo Fantasy Football League for free today]

Gurley goes from one great situation for a running back to another, as the Falcons present another high-powered offense devoid of a workhorse back.

The question is, is he healthy enough to deliver another workhorse-like season? Apparently, Falcons offensive coordinator Dirk Koetter doesnt know either!

Liz Loza and Matt Harmon discuss the issue of Gurleys health in the video above.

Our experts both agree that ultimately, what matters most for Gurley is the workload. Even if hes less than 100 percent (but still able to play at a high level) or isnt as efficient as he used to be, he can still deliver for fantasy purposes if the work is there.

Liz reminds us that even Leonard Fournette who was one of the most inefficient runners in 2019 was fantasy viable, thanks to his workload.

And maybe the return to Georgia will be the reset Gurley needs, as he had so much success in the state at the collegiate level. But that presents another question: Was adding Gurley a football move on behalf of the Falcons, or was it a marketing move? Both Matt and Liz think its probably a bit of both, but the fact remains: If Gurley is secured a starting runners workload in Atlanta, then fantasy players should have some level of interest.

Go here to see the original:
What is the key to Todd Gurley's fantasy value if he's not healthy in 2020? - Yahoo Lifestyle

From Town & Country

Over the weekend, reports surfaced that gave lovers of Venice more than the usual cause for concern. Per a May 13 story in Venezia Today, Harry's Bar, the world famous watering hole that has attracted the likes of Katharine Hepburn, Ernest Hemingway, Frank Lloyd Wright, and Truman Capote, would not be reopening in the wake of the novel coronavirus outbreak.

"Im not opening on Monday, with those guidelines it is going to be impossible. These are silly conditions written by people without ideas and if they stay this way, we wont be opening not on Monday, not ever," the bar's owner Arrigo Cipriani told the paper, per the Evening Standard.

However, a spokesperson for the Cipriani hospitality group, which operates Harry's Bar as well as dozens of other restaurants, bars, events spaces, hotels, and residences across the globe, told Town & Country that this information "is not accurate." They added, "Harrys Bar in Venice is closed at the moment, not permanently closed."

Originally opened by Arrigo's father, Giuseppe Cipriani Sr., in 1931, the bar quickly garnered a glowing reputation and a who's who of celebrity clientele. Having supposedly invented both carpaccio and the peach-and-champagne cocktail the bellini, Harry's has, in its nearly 90-year history, made an indelible mark on the global food and beverage scene, with offshoots in New York, Las Vegas, Moscow, and Abu Dhabi. It was even made a national landmark by the Italian Ministry for Cultural Affairs in 2001. Like many other Italian businesses, Harry's was forced to shut down operations in early March when the COVID-19 pandemic began to take a devastating toll on the country.

As for when Harry's Bar will be reopening in Venice, it's not yet clear, but many bars and restaurants across the country are opening today as Italy begins to lift its restrictions on business operations under the pandemic.

You Might Also Like

The rest is here:
Harry's Bar in Venice Is Not Permanently Closed After All - Yahoo Lifestyle

Click here to read the full article.

Fila is honoring one of the most iconic albums of all time with a legendary sneaker release.

The Fila x Biggie Smalls collection honors the late great rapper Christoper Biggie Smalls Wallace, specifically paying tribute to his debut album Ready to Die, which originally released in 1994. The new capsule includes apparel, accessories and two refreshed takes on the Fila Tennis 88 sneakers inspired by the rapper, also known as The Notorious B.I.G. The collection is available at midnight on May 19 at Fila.com. Both sneakers will reportedly retail for $90.

More from Footwear News

The first iteration of the Fila Tennis 88 x Biggie centers on beige suede uppers with red and black accents and overlays, mirroring the color choice of the Ready to Die album artwork. The unmissable etching of a young baby from the cover art also can be spotted in the insole of the style. The second colorway switches things up with a white smooth leather upper topped off with pops of icy blue layered in with a deeper true blue shade.

In line with the new collection, Fila is also set to partner with the Christopher Wallace Memorial Foundation, an organization founded by Wallaces mother after his passing as a vehicle for giving back to the community primarily through education. The brand plans to donate a pair of childrens shoes to the foundation for each shoe sold on the brands website.

Story continues

The brand first teased the new collection on social media with a glimpse into the insole of the shoes on May 15.

Previously, Fila has collaborated on collections with Brooklyn, N.Y.-based sneaker shop Alumni in addition to a series of capsules with Jason Wu and a few styles inspired by the Ghostbuster films.

Sign up for FN's Newsletter. For the latest news, follow us on Facebook, Twitter, and Instagram.

Read the original:
Fila Honors the Late Rapper Biggie Smalls With a Must-Have Duo of Sneakers - Yahoo Lifestyle